We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Durata’s Study of Skin Infection Drug Dalbavancin Hits Endpoint
Durata’s Study of Skin Infection Drug Dalbavancin Hits Endpoint
January 4, 2013
One of Durata Therapeutics’ two Phase III trials of dalbavancin has met its primary endpoint, bringing the skin infection drug closer to review in the U.S. and Europe.